A Phase 2 interventional study of SR750 tablet and SR750 tablet in Trigeminal Neuralgia, sponsored by Shanghai SIMR Biotechnology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by Shanghai SIMR Biotechnology Co., Ltd. · Phase 2, Interventional, and Treatment
The goal of this clinical trial is to evaluate the efficacy，safety and tolerability of SR750 in patients with trigeminal neuralgia (TN). Patients will receive SR750 (study drug) or placebo for 6 weeks and keep a diary of daily pain. The study duration for each patient is up to 11 weeks.
This is a phase 2, randomized, double-blind study comparing SR750 with placebo in patients with trigeminal neuralgia. It consists of a screening period, a double-blind treatment period, and a post-treatment safety follow-up period. Baseline pain intensity and number of paroxysms will be taken in the run-in period of screening period and will be checked for eligibility. Around 162 eligible subjects will be recruited and randomized into three arms at 1:1:1 ratio to receive SR750 high dose twice a day (BID) , SR750 low dose BID or placebo BID for 6 weeks. Subjects, investigators, all clinical study site staffs, and the Sponsor will remain blinded to treatment assignment during the study. Subjects will be asked to record the number of paroxysms of pain, severity of daily average pain of paroxysms and severity of daily worst pain in e-diary over the last 24 hours every night before going to bed. After completion of double-blind period, subjects will continue to complete the safety follow-up.
135 studies on the registry are indexed under Trigeminal Neuralgia; 44 are open to participants now.
This study's enrollment of 138 is above the median of 40 across 92 interventional studies indexed under Trigeminal Neuralgia.
Browse Trigeminal Neuralgia studies →Shanghai SIMR Biotechnology Co., Ltd. is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Drug: SR750 tablet
Drug: SR750 tablet
Drug: Placebo
SR750 high dose BID orally for 6 weeks
SR750 low dose BID orally for 6 weeks
Placebo
Daily Average Pain Score (DAPS)
Change from baseline to week 6 in the weekly average of the daily average pain score (DAPS) of paroxysms using pain intensity numerical rating scale (PI-NRS).The PI-NRS consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst imaginable pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10.
Time frame: up to week 6
Proportion of responders
Proportion of subjects who meets one of the following criteria, * Patient Global Impression of Change (PGIC) response of "Much Improved" or "Very Much Improved" at Week 6. Subjects will select a value to represent their overall status since the start of the study on a 7-point scale of PGIC on which 1 corresponds to "very much improved", 2 corresponds to "much improved", 3 corresponds to "slightly improved" 4 corresponds to "no change", 5 corresponds to "slightly worse", 6 corresponds to "much worse", and 7 corresponds to "very much worse". * A reduction of ≥2 points from baseline in mean pain score at Week 6 * A reduction of ≥30% from baseline in mean pain score at Week 6 * A reduction of ≥50% from baseline in mean pain score at Week 6 * A reduction of ≥30% from baseline in mean number of paroxysms at Week 6 * A reduction of ≥50% from baseline in mean number of paroxysms at Week 6 * A reduction of ≥30% from baseline in mean worst pain score at Week 6
Time frame: up to week 6
Mean pain score by week
Change from baseline in weekly mean pain score. The daily pain score will be measured by PI-NRS described as above.
Time frame: up to week 6
Mean worst pain score by week
Change from baseline in mean worst pain score by week. The daily worst pain score will be measured by PI-NRS described as above.
Time frame: up to week 6
Mean number of paroxysms by week
Change from baseline in mean number of paroxysms by week
Time frame: up to week 6
Mean continuous pain score by week
Change from baseline in mean continuous pain score by week. The daily continuous pain score will be measured by PI-NRS described as above.
Time frame: up to week 6
Proportion of subjects with continuous pain at week 6
Change of proportion from baseline
Time frame: up to week 6
Hospital Anxiety and Depression Scale (HADS)
Change of HADS from baseline. The HADS is a self-administered questionnaire consisting of two subscales, one for anxiety (HADS-A Subscale) and the other for depression (HADS-D Subscale). Each subscale consists of 7 items, and subjects will rate each item as it applies to them 0 points = absence of anxiety or depression; 3 points = severe anxiety or depression. The HADS-A Subscale analyzes generalized anxiety states, including anxious feelings, restlessness, anxious thoughts, and panic attacks. The HADS-D Subscale focuses on states of loss of interest and reduced pleasure response (reduced enjoyment mood). Each subscale will receive a score from 0 to 21, with bigger number indicating more severe symptom.
Time frame: up to week 6
Use of rescue medication
Including the first time to use rescue medication, total amount and proportion
Time frame: up to week 7
Adverse events
To collect the adverse events during the study
Time frame: up to week 7
Plasma concentration of SR750 and its metabolite
To measure the plasma concentration of SR750 and its metabolite after dosing
Time frame: up to day 43
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai SIMR Biotechnology Co., Ltd.